Astellas Gene Therapies Announces plans to discontinue development of Duchenne gene therapy programs
Last night, based on recent preclinical data, Astellas Gene Therapies announced that the research and development of gene therapy programs AT702, AT751 and AT753 for Duchenne Muscular Dystrophy have been terminated. • AT702 was designed…Learn More
